Results 261 to 270 of about 67,560 (281)

Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction

Sexual Medicine Reviews, 2018
Faysal A Yafi
exaly  

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

Ca-A Cancer Journal for Clinicians, 2011
Timothy A Yap, Johann Sebastian de Bono
exaly  

Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy

Journal of Urology, 2015
Thorsten Schlomm, Pierre Tennstedt, Burkhard Beyer   +2 more
exaly  

Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility

Circulation, 2007
Jayan Nagendran, Stephen L Archer, Rohit Moudgil   +2 more
exaly  

Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis

European Urology Focus, 2017
Marrissa Martyn-St James, Shijie Ren, Eva Kaltenthaler   +2 more
exaly  

Editorial: Tachyphylaxis and Phosphodiesterase Type 5 Inhibitors

The Journal of Urology, 2002
openaire   +1 more source

Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis

European Urology, 2013
Jinqiu Yuan, Chen Mao, Jinling Tang
exaly  

EVIDENCE FOR CONTAMINATION OF HERBAL ERECTILE DYSFUNCTION PRODUCTS WITH PHOSPHODIESTERASE TYPE 5 INHIBITORS

Journal of Urology, 2005
Neil Fleshner
exaly  

Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy

Circulation, 2012
Elisa Giannetta, Andrea Isidori, Nicola Galea   +2 more
exaly  

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors

Ca-A Cancer Journal for Clinicians
Chadi Hage Chehade, Georges Gebrael, Nicolas Sayegh   +2 more
exaly